Healthcare company DexCom, Inc. (NASDAQ: DXCM) announced preliminary results for the fourth quarter of 2023, reporting an estimated double-digit increase in revenues.
- Fourth-quarter revenue, unaudited, is expected to be at least $1.03 billion, which represents an increase of 26% over the same period of 2022
- US revenue is expected to be around $765 million in the December quarter, which is up 26% over the fourth quarter of the prior year
- At $265 million, international revenue is estimated to be higher by 27% from the prior-year quarter
- Stelo, the company’s new glucose sensor for people with type-2 diabetes who do not use insulin, has been submitted to the FDA for review
- For FY24, the company expects revenues of $4.15-4.35 billion, representing expected organic growth of 16-21% Year-over-year
- Full-year adjusted gross profit margin is expected to be approximately 63 – 64%
- The management is looking for an adjusted operating margin of around 20% for fiscal 2024
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q2 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported its second quarter 2024 earnings results today. Net sales increased 4.9% year-over-year to $5 billion. Organic sales increased 9%. Net income attributable to Colgate-Palmolive Company was $731
Key takeaways from Visa’s Q3 2024 earnings report
Credit card behemoth Visa, Inc. (NYSE: V) this week reported mixed results for the June quarter, with earnings matching expectations and sales slightly missing the view. Both numbers grew in
Southwest Airlines (LUV): A look at the airline’s performance in Q2 2024
Shares of Southwest Airlines Co. (NYSE: LUV) were up over 6% on Thursday after the company beat earnings estimates for the second quarter of 2024. The stock has gained 4%
